Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea

Changsoo Kim, Seonkyeong Rhie, Mina Suh, Dae Ryong Kang, Yoon Jung Choi, Geun Ryang Bae, Youngchul Choi, Byung Yool Jun, Joon Soo Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Many studies have investigated the association between Guillain-Barré syndrome (GBS) and vaccinations during the influenza A H1N1 pandemic of 2009 (pH1N1). Based on a nationally representative sample, we estimated the incidence of GBS during the pandemic period in Korea. Materials and methods: All medical records of GBS cases were reviewed in 28 randomly selected hospitals during 2008-2010, and the number of GBS cases at the national level was extrapolated using emergency care utilization data. The GBS rate per 100,000 person-years was estimated in the reference and pandemic periods. Results: The incidence of GBS was 0.63 (95% CI: 0.37-0.89) per 100,000 person-years in the reference period and 0.87 (0.49-1.26) in the pandemic period. During the vaccination season, the pandemic period GBS incidence rate was not significantly higher than the reference period incidence rate (rate ratio: 1.52; 0.99-2.32), but difference was observed among persons aged 20-34 years. Rate of GBS increased after pH1N1 vaccination compared to the reference period (1.46, 1.26-1.68). Discussion: The incidence of GBS increased slightly but not significantly during the pandemic period, although pH1N1 vaccination increased the GBS rate. Therefore, mass influenza vaccination programs should not be precluded on the basis of GBS.

Original languageEnglish
Pages (from-to)1815-1823
Number of pages9
JournalVaccine
Volume33
Issue number15
DOIs
Publication statusPublished - 2015 Apr 8

Fingerprint

Pandemics
pandemic
Korea
influenza
Human Influenza
Korean Peninsula
Vaccination
vaccination
incidence
Incidence
Mass Vaccination
Emergency Medical Services
Medical Records
sampling

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Kim, C., Rhie, S., Suh, M., Kang, D. R., Choi, Y. J., Bae, G. R., ... Lee, J. S. (2015). Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea. Vaccine, 33(15), 1815-1823. https://doi.org/10.1016/j.vaccine.2015.02.035
Kim, Changsoo ; Rhie, Seonkyeong ; Suh, Mina ; Kang, Dae Ryong ; Choi, Yoon Jung ; Bae, Geun Ryang ; Choi, Youngchul ; Jun, Byung Yool ; Lee, Joon Soo. / Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea. In: Vaccine. 2015 ; Vol. 33, No. 15. pp. 1815-1823.
@article{fe37e263c8b94e8080f9f612e4c3eafb,
title = "Pandemic influenza A vaccination and incidence of Guillain-Barr{\'e} syndrome in Korea",
abstract = "Background: Many studies have investigated the association between Guillain-Barr{\'e} syndrome (GBS) and vaccinations during the influenza A H1N1 pandemic of 2009 (pH1N1). Based on a nationally representative sample, we estimated the incidence of GBS during the pandemic period in Korea. Materials and methods: All medical records of GBS cases were reviewed in 28 randomly selected hospitals during 2008-2010, and the number of GBS cases at the national level was extrapolated using emergency care utilization data. The GBS rate per 100,000 person-years was estimated in the reference and pandemic periods. Results: The incidence of GBS was 0.63 (95{\%} CI: 0.37-0.89) per 100,000 person-years in the reference period and 0.87 (0.49-1.26) in the pandemic period. During the vaccination season, the pandemic period GBS incidence rate was not significantly higher than the reference period incidence rate (rate ratio: 1.52; 0.99-2.32), but difference was observed among persons aged 20-34 years. Rate of GBS increased after pH1N1 vaccination compared to the reference period (1.46, 1.26-1.68). Discussion: The incidence of GBS increased slightly but not significantly during the pandemic period, although pH1N1 vaccination increased the GBS rate. Therefore, mass influenza vaccination programs should not be precluded on the basis of GBS.",
author = "Changsoo Kim and Seonkyeong Rhie and Mina Suh and Kang, {Dae Ryong} and Choi, {Yoon Jung} and Bae, {Geun Ryang} and Youngchul Choi and Jun, {Byung Yool} and Lee, {Joon Soo}",
year = "2015",
month = "4",
day = "8",
doi = "10.1016/j.vaccine.2015.02.035",
language = "English",
volume = "33",
pages = "1815--1823",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15",

}

Kim, C, Rhie, S, Suh, M, Kang, DR, Choi, YJ, Bae, GR, Choi, Y, Jun, BY & Lee, JS 2015, 'Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea', Vaccine, vol. 33, no. 15, pp. 1815-1823. https://doi.org/10.1016/j.vaccine.2015.02.035

Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea. / Kim, Changsoo; Rhie, Seonkyeong; Suh, Mina; Kang, Dae Ryong; Choi, Yoon Jung; Bae, Geun Ryang; Choi, Youngchul; Jun, Byung Yool; Lee, Joon Soo.

In: Vaccine, Vol. 33, No. 15, 08.04.2015, p. 1815-1823.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pandemic influenza A vaccination and incidence of Guillain-Barré syndrome in Korea

AU - Kim, Changsoo

AU - Rhie, Seonkyeong

AU - Suh, Mina

AU - Kang, Dae Ryong

AU - Choi, Yoon Jung

AU - Bae, Geun Ryang

AU - Choi, Youngchul

AU - Jun, Byung Yool

AU - Lee, Joon Soo

PY - 2015/4/8

Y1 - 2015/4/8

N2 - Background: Many studies have investigated the association between Guillain-Barré syndrome (GBS) and vaccinations during the influenza A H1N1 pandemic of 2009 (pH1N1). Based on a nationally representative sample, we estimated the incidence of GBS during the pandemic period in Korea. Materials and methods: All medical records of GBS cases were reviewed in 28 randomly selected hospitals during 2008-2010, and the number of GBS cases at the national level was extrapolated using emergency care utilization data. The GBS rate per 100,000 person-years was estimated in the reference and pandemic periods. Results: The incidence of GBS was 0.63 (95% CI: 0.37-0.89) per 100,000 person-years in the reference period and 0.87 (0.49-1.26) in the pandemic period. During the vaccination season, the pandemic period GBS incidence rate was not significantly higher than the reference period incidence rate (rate ratio: 1.52; 0.99-2.32), but difference was observed among persons aged 20-34 years. Rate of GBS increased after pH1N1 vaccination compared to the reference period (1.46, 1.26-1.68). Discussion: The incidence of GBS increased slightly but not significantly during the pandemic period, although pH1N1 vaccination increased the GBS rate. Therefore, mass influenza vaccination programs should not be precluded on the basis of GBS.

AB - Background: Many studies have investigated the association between Guillain-Barré syndrome (GBS) and vaccinations during the influenza A H1N1 pandemic of 2009 (pH1N1). Based on a nationally representative sample, we estimated the incidence of GBS during the pandemic period in Korea. Materials and methods: All medical records of GBS cases were reviewed in 28 randomly selected hospitals during 2008-2010, and the number of GBS cases at the national level was extrapolated using emergency care utilization data. The GBS rate per 100,000 person-years was estimated in the reference and pandemic periods. Results: The incidence of GBS was 0.63 (95% CI: 0.37-0.89) per 100,000 person-years in the reference period and 0.87 (0.49-1.26) in the pandemic period. During the vaccination season, the pandemic period GBS incidence rate was not significantly higher than the reference period incidence rate (rate ratio: 1.52; 0.99-2.32), but difference was observed among persons aged 20-34 years. Rate of GBS increased after pH1N1 vaccination compared to the reference period (1.46, 1.26-1.68). Discussion: The incidence of GBS increased slightly but not significantly during the pandemic period, although pH1N1 vaccination increased the GBS rate. Therefore, mass influenza vaccination programs should not be precluded on the basis of GBS.

UR - http://www.scopus.com/inward/record.url?scp=84925342509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925342509&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.02.035

DO - 10.1016/j.vaccine.2015.02.035

M3 - Article

C2 - 25728315

AN - SCOPUS:84925342509

VL - 33

SP - 1815

EP - 1823

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15

ER -